Eterna Therapeutics
ERNA
20 hedge funds and large institutions have $264K invested in Eterna Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
11% more funds holding
Funds holding: 18 → 20 (+2)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
10% less capital invested
Capital invested by funds: $292K → $264K (-$28.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$65.7K |
| 2 |
Citigroup
New York
|
+$50.3K |
| 3 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
+$22.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$21.6K |
| 5 |
HF
HRT Financial
New York
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.16K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$6.28K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$5.55K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.48K |
ERNA Hedge Fund Activity: Q1 2025 in Review
20 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2025, worth a combined $264K — down 9.6% from $292K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ERNA positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Securities, adding an estimated $65.7K. The largest seller was Millennium Management, exiting entirely with an estimated $13.2K sold.
- 20 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2025, up from 18 in Q4 2024.
- Funds reported $264K of Eterna Therapeutics stock for Q1 2025, down 9.6% quarter-over-quarter.
- 6 funds opened new Eterna Therapeutics positions in Q1 2025 and 4 closed out, a net change of +2 holders.
- The largest Eterna Therapeutics buyer in Q1 2025 was Two Sigma Securities, an estimated $65.7K added.
- The largest Eterna Therapeutics seller in Q1 2025 was Millennium Management, an estimated $13.2K sold.
Based on aggregated 13F filings for Q1 2025.